Chokri Ben Lamine: Platelet Subpopulations and Targeted Therapies Across Evidence Levels
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Study Stage / Evidence Level – Platelet Subpopulation – Targeted Therapies
Reversible P2Y12 inhibitors (ticagrelor / cangrelor)
- Stage: Phase III (established clinical practice)
- PLATO trial – robust RCT evidence – guideline standard in ACS
- Highest level evidence (Class I recommendation in cardiology guidelines)
GPVI inhibitors (glenzocimab, revacept)
- Stage: Phase II clinical trials
- PCI studies – good safety (decreased bleeding)
- Efficacy signal modest – no reduction in MI yet
- Promising but NOT standard of care
PI3K inhibition (LY294002)
- Stage: Preclinical / experimental
- Mechanistic targeting only
- No clinical application currently
COX-2 targeting / aspirin adjustment
- Stage: Mixed clinical data (small trials / observational)
- No consistent benefit – not guideline recommended
- Conceptual explanation for aspirin resistance
Platelet–immune axis (VEGF / PDGF / αIIbβ3 in cancer)
- Stage: Early clinical / exploratory (e.g., APOLLO study)
- Signal for improved outcomes with ICI combinations
- Hypothesis-generating – not standard oncology practice
S100A8/A9 inhibitors (ABR-215757)
- Stage: Preclinical models
- Demonstrated decreased RP-driven thrombosis
- No human outcome trials yet
SGLT2 inhibitors (indirect platelet modulation)
- Stage: Phase III cardiovascular outcome trials (indirect evidence)
- Proven decreased CV events – platelet benefit inferred
- Not platelet-specific indication but clinically relevant
Summary hierarchy (very high yield)
Phase III / Standard: Ticagrelor / Cangrelor
Phase II / Emerging: GPVI inhibitors
Preclinical / Experimental:
- PI3K inhibitors
- S100A8/A9 inhibitors
Hypothesis / Mixed evidence:
- COX-2 targeting
- Platelet–immune modulation
Clinical pearl
- Only P2Y12 reversible inhibitors currently translate platelet subpopulation biology into routine practice.
- Everything else is precision medicine pipeline (future hematology/cardiology integration).”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Apr 14, 2026, 15:43Webinar on Aplastic Anemia Clinical Case – ASH
-
Apr 14, 2026, 15:42Heghine Khachatryan: Endometriosis Is Not Only a Pain Disorder
-
Apr 14, 2026, 15:36Alisha Tuck: Navigating the First Trimester with Ultrasound and Anticoagulation Management
-
Apr 14, 2026, 15:26Tijjani Balas: The End of ‘Type O Negative’ Shortages? – A New Era in Blood Transfusion
-
Apr 14, 2026, 15:07Carlos Henrique Del Carlo: HFpEF Reimagined as an Adipose Tissue Driven Disease
-
Apr 14, 2026, 15:05Matteo Foschi: ASPERA-R Study Reveals Competing Causes Of Breakthrough Stroke On Anticoagulation
-
Apr 14, 2026, 14:48Samwel Mikaye: From Virchow’s Triad to Prevention of PE in Patients with DVT
-
Apr 14, 2026, 14:43Chokri Ben Lamine: Diamond – Blackfan Anemia and Congenital Dyserythropoietic Anemia Pearls
-
Apr 14, 2026, 14:14From the Clinical Transfusion Working Party – 2025 International Platelet Transfusion Guidelines – ISBT